Lack of Correlation Between the CCR5-Δ32 Mutation and Acute Myeloid Leukemia in Iranian Patients

Indian Journal of Hematology and Blood Transfusion

Volumn 31, Issue 1, 2015, Pages 29-31

  Khorramdelazad, Hossein ^a   Mortazavi, Yousef ^b   Momeni, Mohammad ^a   Arababadi, Mohammad Kazemi ^a   Khandany, Behjat Kalantary ^c   Moogooei, Mozhgan ^a   Hassanshahi, Gholamhossein ^a  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute myeloblastic leukemia; CCR5 32 mutation; Chemokine

Indexed keywords

EID: 84937201410     PISSN: 09714502     EISSN: 09740449     Source Type: Journal    
DOI: 10.1007/s12288-014-0408-y     Document Type: Article

References (19)

1. Sandhu SK, Sekeres MA (2008) Myelodysplastic syndromes: more prevalent than we know. Geriatrics 63(11):10–17
2. Karimi M, Mehrabani D, Yarmohammadi H, Jahromi FS (2008) The prevalence of signs and symptoms of childhood leukemia and lymphoma in Fars Province Southern Iran. Cancer Detect Prev 32(2):178–183
3. Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock W (2011) Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol 38(2):196–214
4. Azin H, Vazirinejad R, Ahmadabadi BN, Khorramdelazad H, Zarandi ER, Arababadi MK, et al (2012) The SDF-1 3′A genetic variation of the chemokine SDF-1α (CXCL12) in parallel with its increased circulating levels is associated with susceptibility to MS: a study on iranian multiple sclerosis patients. J Mol Neurosci 47(3): 431–436. doi:10.1007/s12031-011-9672-6
5. Derakhshan R, Arababadi MK, Ahmadi Z, Karimababadi MN, Salehabadi VA, Abedinzadeh M, et al (2012) Increased circulating levels of SDF-1 (CXCL12) in type 2 diabetic patients are correlated to disease state but are unrelated to polymorphism of the SDF-1β gene in the Iranian population. Inflammation 35(3):900–904
6. Mirandola L, Chiriva-Internati M, Montagna D, Locatelli F, Zecca M, Ranzani M et al (2011) Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol 2011(7):3015
7. Jin Q, Agrawal L, Meyer L, Tubiana R, Theodorou I, Alkhatib G (2008) CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects. J Virol 82(5):2418–2426
8. Singh H, Sachan R, Jain M, Mittal B (2008) CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res 17(2):87–91
9. Nahon P, Sutton A, Rufat P, Simon C, Trinchet JC, Gattegno L et al (2008) Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 14(5):713–719
10. Guerini FR, Delbue S, Zanzottera M, Agliardi C, Saresella M, Mancuso R et al (2008) Analysis of CCR5, CCR2, SDF1 and RANTES gene polymorphisms in subjects with HIV-related PML and not determined leukoencephalopathy. Biomed Pharmacother 62(1):26–30
11. Abousaidi H, Vazirinejad R, Arababadi MK, Rafatpanah H, Pourfathollah AA, Derakhshan R et al (2011) Lack of association between chemokine receptor 5 (CCR5) delta32 mutation and pathogenesis of asthma in Iranian patients. South Med J 104(6):422–425
12. Arababadi MK, Hassanshahi G, Azin H, Salehabad VA, Araste M, Pourali R et al (2010) No association between CCR5-Δ32 mutation and multiple sclerosis in patients of south-eastern of Iran. Lab Medicine 41:31–33
13. Arababadi MK, Naghavi N, Hassanshahi G, Mahmoodi M (2009) Is CCR5-Delta32 mutation associated with diabetic nephropathy in type 2 diabetes? Ann Saudi Med 29(5):413
14. Sun Y, Dong LJ, Tian F, Wang SQ, Jia ZL, Huang J et al (2004) Identification of acute leukemia-specific genes from leukemia recipient/sibling donor pairs by distinguishing study with oligonucleotide microarrays. Zhongguo Shi Yan Xue Ye Xue Za Zhi 12(4):450–454
15. Ferrajoli A, Talpaz M, Zipf TF, Hirsch-Ginsberg C, Estey E, Wolpe SD et al (1994) Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha. Leukemia 8(5):798–805
16. Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM (2012) Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood 119(2):540–550
17. Owen-Lynch PJ, Adams JA, Brereton ML, Czaplewski LG, Whetton AD, Yin JA (1996) The effect of the chemokine rhMIP-1 alpha, and a non-aggregating variant BB-10010, on blast cells from patients with acute myeloid leukaemia. Br J Haematol 95(1):77–84
18. Faaij CM, Willemze AJ, Revesz T, Balzarolo M, Tensen CP, Hoogeboom M et al (2010) Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr Blood Cancer 55(2):344–348
19. Serrano-Lopez J, Sanchez-Garcia J, Serrano J, Alvarez-Rivas MA, Garcia-Castellano JM, Roman-Gomez J et al (2011) Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia. Transfusion 51(7):1546–1555